In accordance with Listing Rule 4.2A, attached is the Half-Year Financial Report (reviewed) on the consolidated results of Circadian Technologies Limited (‘Circadian’ or ‘Group’) for the half-year ended 31 December 2011. Previous corresponding period is the financial year ended 30 June 2011 and the half year ended 31 December 2010.
Results for the period predominantly reflect the Group’s investment in advancing its cancer treatment programs VGX-100, VGX-200 and VGX-300. The development, including associated costs, of the VEGFR3 antibody as a cancer treatment, licensed to ImClone Inc (owned by Eli Lilly, NYSE:LLY) and the Cancers of Unknown Primaries (CUP) diagnostic, licensed to Healthscope Limited (ASX:HSP), are being undertaken by those respective licensees.
An analysis of the financial results is provided in the attached Appendix 4D Half-Year Financial Report.
For details regarding Circadian’s half-year results and operational highlights/events refer to the Half-Year Financial Report attached.
This letter and the attached Half-Year Financial Report form part of this announcement to the Australian Stock Exchange Limited, and should be read in conjunction with the Company’s Annual Report for the year ended 30 June 2011.
To view full Report please download PDF below: